fr
Article scientifique
Anglais

Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures

Publié dansJournal of acquired immune deficiency syndromes, vol. 53, no. 4, p. 464-471
Date de publication2010
Résumé

BACKGROUND: Raltegravir (RAL) achieved remarkable virologic suppression rates in randomized-clinical trials, but today efficacy data and factors for treatment failures in a routine clinical care setting are limited. METHODS: First, factors associated with a switch to RAL were identified with a logistic regression including patients from the Swiss HIV Cohort Study with a history of 3 class failure (n = 423). Second, predictors for virologic outcome were identified in an intent-to-treat analysis including all patients who received RAL. Last observation carried forward imputation was used to determine week 24 response rate (HIV-1 RNA >or= 50 copies/mL). RESULTS: The predominant factor associated with a switch to RAL in patients with suppressed baseline RNA was a regimen containing enfuvirtide [odds ratio 41.9 (95% confidence interval: 11.6-151.6)]. Efficacy analysis showed an overall response rate of 80.9% (152/188), whereas 71.8% (84/117) and 95.8% (68/71) showed viral suppression when stratified for detectable and undetectable RNA at baseline, respectively. Overall CD4 cell counts increased significantly by 42 cells/microL (P < 0.001). Characteristics of failures were a genotypic sensitivity score of the background regimen

Mots-clés
  • Anti-HIV Agents/ therapeutic use
  • Antiretroviral Therapy, Highly Active/ methods
  • CD4 Lymphocyte Count
  • Female
  • HIV Infections/ drug therapy
  • Humans
  • Male
  • Pyrrolidinones/ therapeutic use
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Viral Load
Structure d'affiliation Pas une publication de l'UNIGE
Citation (format ISO)
SCHERRER, A. U. et al. Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. In: Journal of acquired immune deficiency syndromes, 2010, vol. 53, n° 4, p. 464–471. doi: 10.1097/QAI.0b013e3181bca4ec
Fichiers principaux (1)
Article
accessLevelRestricted
Identifiants
ISSN du journal1525-4135
556vues
0téléchargements

Informations techniques

Création21/06/2010 10:26:21
Première validation21/06/2010 10:26:21
Heure de mise à jour14/03/2023 15:45:32
Changement de statut14/03/2023 15:45:32
Dernière indexation12/02/2024 18:37:19
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack